These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21858527)

  • 1. Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide.
    Frampas E; Maurel C; Remaud-Le Saëc P; Mauxion T; Faivre-Chauvet A; Davodeau F; Goldenberg DM; Bardiès M; Barbet J
    Eur J Nucl Med Mol Imaging; 2011 Dec; 38(12):2153-64. PubMed ID: 21858527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
    Heskamp S; Hernandez R; Molkenboer-Kuenen JDM; Essler M; Bruchertseifer F; Morgenstern A; Steenbergen EJ; Cai W; Seidl C; McBride WJ; Goldenberg DM; Boerman OC
    J Nucl Med; 2017 Jun; 58(6):926-933. PubMed ID: 28232604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a Bivalent
    Vaughn BA; Lee SG; Vargas DB; Seo S; Rinne SS; Xu H; Guo HF; Le Roux AB; Gajecki L; Krebs S; Yang G; Ouerfelli O; Zanzonico PB; Fung EK; St Jean S; Carrasco SE; Jungbluth A; Cheung NKV; Larson SM; Veach DR; Cheal SM
    J Nucl Med; 2024 Oct; 65(10):1611-1618. PubMed ID: 39168519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.
    Cheal SM; Fung EK; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Wittrup KD; Cheung NV; Larson SM
    J Nucl Med; 2017 Nov; 58(11):1735-1742. PubMed ID: 28705917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer.
    Schoffelen R; Woliner-van der Weg W; Visser EP; Goldenberg DM; Sharkey RM; McBride WJ; Chang CH; Rossi EA; van der Graaf WT; Oyen WJ; Boerman OC
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1593-602. PubMed ID: 24643780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
    Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
    Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
    Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
    Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept.
    Rondon A; Schmitt S; Briat A; Ty N; Maigne L; Quintana M; Membreno R; Zeglis BM; Navarro-Teulon I; Pouget JP; Chezal JM; Miot-Noirault E; Moreau E; Degoul F
    Theranostics; 2019; 9(22):6706-6718. PubMed ID: 31588245
    [No Abstract]   [Full Text] [Related]  

  • 10. Alpha radioimmunotherapy using
    Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
    Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients.
    Bodet-Milin C; Ferrer L; Rauscher A; Masson D; Rbah-Vidal L; Faivre-Chauvet A; Cerato E; Rousseau C; Hureaux J; Couturier O; Salaün PY; Goldenberg DM; Sharkey RM; Kraeber-Bodéré F; Barbet J
    Front Med (Lausanne); 2015; 2():84. PubMed ID: 26640780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
    Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
    J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward the Optimization of Click-Mediated Pretargeted Radioimmunotherapy.
    Membreno R; Keinänen OM; Cook BE; Tully KM; Fung KC; Lewis JS; Zeglis BM
    Mol Pharm; 2019 May; 16(5):2259-2263. PubMed ID: 30912951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
    Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
    J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT).
    Urbano N; Papi S; Ginanneschi M; De Santis R; Pace S; Lindstedt R; Ferrari L; Choi S; Paganelli G; Chinol M
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):68-77. PubMed ID: 16755333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.
    Cheal SM; Xu H; Guo HF; Lee SG; Punzalan B; Chalasani S; Fung EK; Jungbluth A; Zanzonico PB; Carrasquillo JA; O'Donoghue J; Smith-Jones PM; Wittrup KD; Cheung NV; Larson SM
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):925-937. PubMed ID: 26596724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
    Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide.
    van Rij CM; Frielink C; Goldenberg DM; Sharkey RM; Lütje S; McBride WJ; Oyen WJ; Boerman OC
    Cancer Biother Radiopharm; 2014 Oct; 29(8):323-9. PubMed ID: 25226447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
    Karacay H; Sharkey RM; McBride WJ; Griffiths GL; Qu Z; Chang K; Hansen HJ; Goldenberg DM
    Bioconjug Chem; 2002; 13(5):1054-70. PubMed ID: 12236788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.